First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Jonas BerghCarla Giorgetti

Abstract

To investigate whether sunitinib plus docetaxel improves clinical outcomes for patients with human epidermal growth factor receptor 2 (HER2)/neu-negative advanced breast cancer (ABC) versus docetaxel alone. In this phase III study, patients were randomly assigned to open-label combination therapy (sunitinib 37.5 mg/d, days 2 to 15 every 3 weeks; and docetaxel 75 mg/m(2), day 1 every 3 weeks) or monotherapy (docetaxel 100 mg/m(2) every 3 weeks). Progression-free survival (PFS) was the primary end point. Two hundred ninety-six patients were randomly assigned to combination therapy, and 297 patients were assigned to monotherapy. Median PFS times were 8.6 and 8.3 months with combination therapy and monotherapy, respectively (hazard ratio, 0.92; one-sided P = .265). The objective response rate (ORR) was significantly higher with the combination (55%) than with monotherapy (42%; one-sided P = .001). Duration of response was similar in both arms (7.5 months with the combination v 7.2 months with monotherapy). Median overall survival (OS) times were 24.8 and 25.5 months with combination therapy and monotherapy, respectively (one-sided P = .904). There were 107 deaths with the combination and 91 deaths with monotherapy. The frequency of...Continue Reading

References

Jan 10, 2004·Clinical & Experimental Metastasis·Lesley J MurrayNancy K Pryer
Feb 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathy D MillerHope S Rugo
Oct 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vernon HarveySoeren Cold
Aug 31, 2007·Nature Clinical Practice. Oncology·Susana BanerjeeLesley-Ann Martin
Dec 28, 2007·The New England Journal of Medicine·Kathy MillerNancy E Davidson
Mar 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harold J BursteinKathy D Miller
Dec 3, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jonas Bergh
Jun 3, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerRobert A Figlin
May 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David W MilesGilles Romieu

❮ Previous
Next ❯

Citations

Oct 18, 2012·Breast Cancer Research and Treatment·Denise A YardleyDennis L Citrin
Jan 30, 2013·Breast Cancer Research and Treatment·Soley Bayraktar, Stefan Glück
Sep 27, 2012·Journal of Mammary Gland Biology and Neoplasia·Robert S Kerbel
Nov 4, 2011·Current Treatment Options in Oncology·Christos Vaklavas, Andres Forero-Torres
Oct 1, 2013·The Breast : Official Journal of the European Society of Mastology·Robert S KerbelShan Man
Sep 25, 2012·Nature Reviews. Cancer·Barbara Sennino, Donald M McDonald
Aug 18, 2012·Journal of Translational Medicine·Kiana KeyvanjahWilliam Carley
Oct 29, 2010·Journal of Hematology & Oncology·Rafael Santana-Davila, Edith A Perez
Jun 21, 2012·Breast Cancer Research : BCR·Carmen CriscitielloMartine J Piccart-Gebhart
Jul 31, 2012·The Oncologist·Sangeetha ReddyVirginia Kaklamani
Nov 29, 2013·International Journal of Molecular Sciences·Elvira D'Ippolito, Marilena V Iorio
Feb 25, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Katsuhiko HiguchiUNKNOWN Tokyo Cooperative Oncology Group, Tokyo, Japan
May 11, 2012·Future Medicinal Chemistry·Máximo de la VegaRicardo H Alvarez
Jan 30, 2014·Japanese Journal of Clinical Oncology·Elham Fakhrejahani, Masakazu Toi
Feb 18, 2014·Cancer Treatment Reviews·Annalisa BramatiNicla Maria La Verde
Jul 6, 2014·The New England Journal of Medicine·Michelle A Maynard, Stephen A Huang
Dec 21, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C TwelvesJ H Schiller
Jun 18, 2014·Nature Reviews. Clinical Oncology·Denis LacombeRoger Stupp
Dec 3, 2014·Gynécologie, obstétrique & fertilité·F CoussyM Espié
Oct 19, 2014·Journal of the National Cancer Institute·Philip WongDian Wang
Jan 20, 2015·Expert Review of Clinical Pharmacology·Claudia BozzaGiuseppe Aprile
Dec 7, 2013·Expert Review of Anticancer Therapy·Ioannis D XynosCarlo Palmieri
Jan 19, 2016·Nature Reviews. Drug Discovery·Napoleone Ferrara, Anthony P Adamis
Jul 16, 2014·Expert Opinion on Biological Therapy·Geraldine O'Sullivan Coyne, Mauricio Burotto
Nov 8, 2015·Advanced Drug Delivery Reviews·Quanyin HuZhen Gu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.

Carcinoma, Lobular

Lobular carcinoma is an invasive type of breast cancer in which lobules, areas of the breast that produce milk, undergo malignant transformation. Here is the latest research.